OP
TVTX icon

ORG Partners’s Travere Therapeutics TVTX Stock Holding History

ORG Partners’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$3.74K Buy
+98
New +$3.19K ﹤0.01% 1297

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

ORG Partners's TVTX Position: Q4 2025 in Review

ORG Partners opened a new position in Travere Therapeutics (TVTX) in Q4 2025: 98 shares worth $3.74K. The stake represents ﹤0.01% of the portfolio and ranks #1297 among its holdings.

278 funds tracked by Wall St. Rank hold TVTX as of Q4 2025.

  • ORG Partners held 98 shares of Travere Therapeutics worth $3.74K as of Q4 2025.
  • Travere Therapeutics was a new ORG Partners position in Q4 2025.
  • Travere Therapeutics made up ﹤0.01% of ORG Partners's portfolio in Q4 2025, its #1297 holding.
  • 278 funds tracked by Wall St. Rank held Travere Therapeutics as of Q4 2025.

Based on ORG Partners's 13F filing for Q4 2025, filed 14 Jan 2026.